search
Back to results

Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice

Primary Purpose

Head Lice

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Summers 5% L.A.
Sponsored by
Summers Laboratories
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Head Lice

Eligibility Criteria

6 Months - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Males and females 6 months of age or older.
  2. Have an active infestation with Pediculus capitis, the human head louse, with at least three live lice at baseline.
  3. Agree not to use any other pediculicides or medicated hair-grooming products during the duration of the study.
  4. Be healthy, non-febrile, and not suffering from an infection likely to require antibiotic therapy during the study period.
  5. Subject or guardian is able to understand the new HIPAA regulations and sign the HIPAA form.
  6. Subject or guardian has read, understood, and signed appropriate informed consent in English. If English is not the primary language, the information about the study must be explained in their language and a copy of the informed consent must be in that language.
  7. Subject is willing to participate in the study, and abide by the protocol requirements.

Exclusion Criteria:

  1. Participation in any clinical study within the past 30 days.
  2. Known hypersensitivity to any ingredient in the product formulation.

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Treatment success is defined as the absence of live lice.

    Secondary Outcome Measures

    The cumulative proportions of subjects determined to be treatment failures at the Second Evaluation Visit.

    Full Information

    First Posted
    May 25, 2007
    Last Updated
    May 25, 2007
    Sponsor
    Summers Laboratories
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00479310
    Brief Title
    Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice
    Official Title
    A Multi-Center, Randomized, Vehicle Controlled, Double Blind Clinical Trial to Evaluate the Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.) for the Treatment of Head Lice.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2007
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2006 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Summers Laboratories

    4. Oversight

    5. Study Description

    Brief Summary
    A Multi-center, Randomized, Vehicle Controlled, Double Blind Clinical Trial to Evaluate the Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.) for the treatment of Head Lice.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Head Lice

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    Double
    Allocation
    Randomized
    Enrollment
    120 (false)

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Summers 5% L.A.
    Primary Outcome Measure Information:
    Title
    Treatment success is defined as the absence of live lice.
    Secondary Outcome Measure Information:
    Title
    The cumulative proportions of subjects determined to be treatment failures at the Second Evaluation Visit.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    6 Months
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Males and females 6 months of age or older. Have an active infestation with Pediculus capitis, the human head louse, with at least three live lice at baseline. Agree not to use any other pediculicides or medicated hair-grooming products during the duration of the study. Be healthy, non-febrile, and not suffering from an infection likely to require antibiotic therapy during the study period. Subject or guardian is able to understand the new HIPAA regulations and sign the HIPAA form. Subject or guardian has read, understood, and signed appropriate informed consent in English. If English is not the primary language, the information about the study must be explained in their language and a copy of the informed consent must be in that language. Subject is willing to participate in the study, and abide by the protocol requirements. Exclusion Criteria: Participation in any clinical study within the past 30 days. Known hypersensitivity to any ingredient in the product formulation.

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    20199404
    Citation
    Meinking TL, Villar ME, Vicaria M, Eyerdam DH, Paquet D, Mertz-Rivera K, Rivera HF, Hiriart J, Reyna S. The clinical trials supporting benzyl alcohol lotion 5% (Ulesfia): a safe and effective topical treatment for head lice (pediculosis humanus capitis). Pediatr Dermatol. 2010 Jan-Feb;27(1):19-24. doi: 10.1111/j.1525-1470.2009.01059.x.
    Results Reference
    derived
    Links:
    URL
    http://www.sumlab.com
    Description
    Related Info

    Learn more about this trial

    Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice

    We'll reach out to this number within 24 hrs